• Sunitinib and TRIB3: Overcoming RTK Inhibitor Resistance in

  2026-07-31

  Explore how Sunitinib, a multi-targeted receptor tyrosine kinase inhibitor, is revolutionizing renal cell carcinoma research by targeting TRIB3-mediated resistance. This article offers a deeper mechanistic understanding and advanced protocol strategies, setting it apart from standard assay guides.

• NLRP3 Inflammasome and Coagulation in Endotoxemic Mice: New

  2026-07-31

  This study elucidates the distinct contributions of TLR4, caspase-11, and the NLRP3 inflammasome to tissue factor-positive extracellular vesicle (EV) release and coagulation activation in a mouse endotoxemia model. The findings clarify that while TLR4 dominates early procoagulant signaling, caspase-11 and NLRP3 exert more nuanced, time-dependent effects, refining our understanding of inflammatory disease mechanisms and experimental design.

• GST-Mediated Resistance in M. usitatus: Role of Diethylmalea

  2026-07-30

  The reference study reveals that glutathione S-transferase (GST) activity underpins Megalurothrips usitatus resistance to lambda-cyhalothrin by enhancing antioxidant defenses. By inhibiting GST with diethyl maleate, researchers significantly increased the pest's sensitivity to insecticide, offering direct mechanistic insight for resistance management and oxidative stress research.

• Pazopanib (GW-786034): Mechanistic Insights and ATRX-Deficie

  2026-07-30

  Explore the advanced mechanism of Pazopanib (GW-786034) as a multi-targeted RTK inhibitor and its strategic application in ATRX-deficient cancer models. This article provides unique, data-driven guidance for translational research, expanding on current knowledge of angiogenesis inhibition in cancer biology.

• M344: Precision HDAC Inhibition for Translational Oncology

  2026-07-29

  This thought-leadership article explores the mechanistic basis and translational promise of M344, a potent histone deacetylase inhibitor, for researchers targeting neuroblastoma, breast cancer, and HIV-1 latency. We integrate recent academic evidence and best practices to guide experimental design and strategic positioning, highlighting how M344—available from APExBIO—outperforms conventional HDAC inhibitors and unlocks new therapeutic avenues.

• Disentangling Drug Responses: Improved In Vitro Metrics for

  2026-07-29

  Schwartz's dissertation introduces a refined framework for evaluating anti-cancer drug responses by distinguishing between proliferative arrest and cell death using separate viability metrics. This nuanced approach enables more precise analysis of tyrosine kinase inhibitors, such as Tivozanib (AV-951), in preclinical oncology workflows.

• Geneticin (G-418 Sulfate): Epigenetic Selection and Antivira

  2026-07-28

  Discover how Geneticin (G-418 Sulfate) enables advanced genetic engineering and antiviral research through precise ribosomal inhibition and epigenetic selection. This article uniquely explores the integration of G418 with emerging differentiation therapy concepts for next-generation cell models.

• AAL-993 for Reliable Tumor Angiogenesis Assays: Best Practic

  2026-07-28

  AAL-993 (SKU C3730) is a potent VEGF receptor inhibitor providing consistent, data-backed solutions for angiogenesis and tumor growth research. This article contextualizes AAL-993’s value for cell viability and anti-angiogenic assays, addressing real laboratory challenges and offering scenario-driven guidance for effective experimental design and product selection.

• ECL Chemiluminescent Substrate Detection Kit: Enhanced Assay

  2026-07-27

  The ECL Chemiluminescent Substrate Detection Kit (Enhanced) delivers ultra-sensitive, low-background protein detection for advanced western blot workflows. Its robust signal stability, straightforward protocol, and broad imaging compatibility empower researchers in translational and mechanistic studies, especially where signal amplification is critical.

• Dissecting Drug Response In Vitro: Lessons from Schwartz et

  2026-07-27

  Schwartz's dissertation introduces a refined approach to in vitro evaluation of anti-cancer drugs by differentiating between growth inhibition and cell death. This methodological advance clarifies the interpretation of drug efficacy, with implications for the design and analysis of preclinical oncology studies.

• Pazopanib (GW-786034): Applied Protocols for Advanced Cancer

  2026-07-26

  Pazopanib (GW-786034) empowers cancer researchers with targeted, multi-pathway inhibition—particularly in challenging ATRX-deficient glioma models. This article delivers actionable workflows, protocol optimizations, and troubleshooting guidance, translating recent mechanistic breakthroughs into practical experimental strategies.

• Phosbind Biotin LC: Practical Guide for Phosphorylation Dete

  2026-07-25

  Phosbind Biotin LC offers a sequence-independent solution for detecting phosphorylated proteins on PVDF membranes, especially in Western Blot workflows where phospho-specific antibodies are unavailable or impractical. It is not suited for aqueous-only protocols or applications requiring long-term storage of working solutions.

• TCF25 Regulates Lysosomal Acidification and Cell Death via V

  2026-07-24

  Ren et al. (2025) identify TCF25 as a nutrient sensor that enhances lysosomal acidification through V-ATPase during glucose starvation, orchestrating cellular adaptation and lysosome-dependent cell death. This mechanistic insight advances understanding of metabolic stress responses and highlights potential molecular targets for metabolic and ischemic disorders.

• Network Pharmacology Reveals SFI’s Anti-Glioma Mechanism via

  2026-07-24

  This study applies network pharmacology to elucidate how Shenqi Fuzheng injection (SFI) inhibits glioma proliferation and migration, identifying the SRC/PI3K/AKT signaling pathway as a central molecular target. The findings clarify SFI’s anti-glioma mechanism and suggest actionable signaling nodes for anti-angiogenic and tumor inhibition research.

• Sunitinib (SKU B1045): Resolving Lab Challenges in RTK Inhib

  2026-07-23

  This article delivers a scenario-driven, evidence-based guide for using Sunitinib (SKU B1045) in cell viability and cancer pathway research. It addresses practical laboratory challenges—ranging from assay reproducibility to product selection—by referencing validated protocols and recent literature. APExBIO’s Sunitinib is positioned as a reliable, high-quality reagent for sensitive and reproducible RTK inhibition studies.

15626 records 1/1042 page Next 12345 下5页 Last page